Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 3 art units • 6 examiners • 0 of 7 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. maintains a portfolio with 7 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 6 distinct examiners and 3 distinct art units. This level of activity reflects an active prosecution effort involving multiple technical specialties within the biotech sector, where different examiners may focus on distinct aspects of the pharmaceutical claims.
MONTANARI, DAVID A is the busiest examiner, currently overseeing 2 busiest examiner pending actions. While most examiners handle a single case, this specific individual manages a larger portion of the workload. The involvement of 3 distinct art units indicates that the company's pharmaceutical innovations are being reviewed for various biological and chemical properties, requiring a multifaceted legal strategy to address the diverse requirements of different patent office divisions. This distribution suggests a broad research and development focus that spans multiple regulatory and technical categories.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (14%) |
| Double-patenting + other | 2 (29%) |
| Multi-statute (no §101) | 4 (57%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MONTANARI, DAVID A | 2 | 64.7% | +49.0% |
| OUSPENSKI, ILIA I | 1 | 77.5% | +20.4% |
| KIM, TAEYOON | 1 | 51.5% | +52.1% |
| ARON, KIMBERLY A | 1 | 54.5% | +35.2% |
| VIVLEMORE, TRACY ANN | 1 | 73.0% | +6.6% |
| ABBOTT, KODYE LEE | 1 | 53.1% | +71.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18025990 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GLP1R | MONTANARI, DAVID A | 20d |
| 18025302 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CCR8 | MONTANARI, DAVID A | 29d |
| 18702039 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENES | KIM, TAEYOON | — |
| 17631048 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC IL33 | ABBOTT, KODYE LEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18025990 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GLP1R | MONTANARI, DAVID A | 20d |
| 18025302 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CCR8 | MONTANARI, DAVID A | 29d |
| 18643334 | MODIFIED IMMUNOGLOBULINS | OUSPENSKI, ILIA I | — |
| 18702039 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENES | KIM, TAEYOON | — |
| 18634364 | GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS | ARON, KIMBERLY A | — |
| 17631048 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC IL33 | ABBOTT, KODYE LEE | — |
| Art Unit | Apps |
|---|---|
| 1632 | 2 |
| 1638 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18643334 | MODIFIED IMMUNOGLOBULINS | OUSPENSKI, ILIA I | — | §102§112DP | Non-Final OA | — | Pending | Apr 23, 2024 |
| 18702039 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENES | KIM, TAEYOON | — | §102§103 | Non-Final OA | — | Pending | Apr 17, 2024 |
| 18634364 | GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS | ARON, KIMBERLY A | — | §102§103§112DP | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18273631 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC FCRN | VIVLEMORE, TRACY ANN | 1638 | §103 | Non-Final OA | 28d overdue | Pending | Jul 21, 2023 |
| 18025990 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GLP1R | MONTANARI, DAVID A | 1632 | §102§103 | Final Rejection | 20d | Pending | Mar 13, 2023 |
| 18025302 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CCR8 | MONTANARI, DAVID A | 1632 | §102§103 | Final Rejection | 29d | Pending | Mar 08, 2023 |
| 17631048 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC IL33 | ABBOTT, KODYE LEE | 1634 | §103§112 | Non-Final OA | — | Pending | Jan 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial